X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The grant will support further development of novel neuroplastogen and ibogaine analog, DLX-007, a novel, first-in-class, neuroplastogen being evaluated in a range of substance use disorders (SUDs), including opioid and stimulant use.
Lead Product(s): DLX-007
Therapeutic Area: Psychiatry/Psychology Product Name: DLX-007
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Funding December 13, 2023
Details:
DLX-001 is the first of several psychoplastogens to be approved for human trials. It promotes rapid and enduring neuroplasticity, matching or exceeding the efficacy of natural psychedelic compounds, without hallucinatory responses even at high doses.
Lead Product(s): DLX-001
Therapeutic Area: Psychiatry/Psychology Product Name: DLX-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
DLX-001 is the first of several psychoplastogens to be approved for human trials. It promotes rapid and enduring neuroplasticity, matching or exceeding the efficacy of natural psychedelic compounds, without hallucinatory responses even at high doses.
Lead Product(s): DLX-001
Therapeutic Area: Psychiatry/Psychology Product Name: DLX-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
Delix have partnered with Cellectricon to create novel assays to measure the structural and functional plasticity effects of Delix's psychoplastogen compounds using cutting-edge technologies.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Cellectricon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 14, 2023
Details:
Under the partnership, The National Institute on Drug Abuse (NIDA) will test one of Delix's lead clinical candidates DLX-7, non-hallucinogenic and non-toxic ibogaine analog, for use in treating a range of substance use disorders.
Lead Product(s): DLX-7
Therapeutic Area: Oncology Product Name: DLX-7
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 07, 2021
Details:
The Company expects to use the proceeds to advance two lead candidates through Phase 1 clinical trials, DLX-1 and DLX-7, which are currently undergoing pre-IND safety and toxicology studies to enable clinical trials.
Lead Product(s): DLX-1
Therapeutic Area: Neurology Product Name: DLX-1
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARTIS Ventures
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 27, 2021
Details:
The paper reveals DLX-1—a new compound inspired by the chemical structures of common psychedelic substances that demonstrates sustained antidepressant effects but without hallucinogenic properties.
Lead Product(s): AAZ
Therapeutic Area: Psychiatry/Psychology Product Name: DLX-1
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
